1-2 of 2
Daniel Chan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

Alexey Danilov, Michael T. Tees, Krish Patel, William G. Wierda, Manish Patel, Ian W. Flinn, Tahir Latif, Weiyun Ai, Meghan C. Thompson, Michael L. Wang, Clare Sun, Deborah M. Stephens, Michael J Thirman, Melissa Gessner, Johannes Wolff, Amanda Schwab, May Tan, Daniel Chan, Erin Meredith, Adrian Wiestner
Journal: Blood
Blood (2023) 142 (Supplement 1): 4463.
https://doi.org/10.1182/blood-2023-179872
Published: 2023
Journal Articles

A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including DLBCL

Graham P. Collins, William Townsend, Ahmed Abdulgawad, Swathi Namburi, Anja Williams, Ana Filipa Palma DosReis, Matthew G. Krebs, Jeff Evans, Sarah P. Blagden, Ruth Plummer, Daniel Hochhauser, Adam Sharp, George Cole, Seema Rogers, Daniel Chan, Sarah Whelan, Dima El-Sharkawi
Journal: Blood
Blood (2023) 142 (Supplement 1): 3093.
https://doi.org/10.1182/blood-2023-172875
Published: 2023